Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells-Reference-Cited by-同舟云学术

Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells

Published:2018-08-03 Issue:1 Volume:19 Page:
ISSN:1471-2172
Container-title:BMC Immunology
language:en
Short-container-title:BMC Immunol

Author:

Shiozawa Masayuki,Chang Chuan-Hsin,Huang Yi-Chun,Chen Yi-Ching,Chi Mau-Shin,Hao Hsu-Chao,Chang Yue-Cune,Takeda Satoru,Chi Kwan-Hwa,Wang Yu-Shan

Funder

Ministry of Science and Technology

Publisher

Springer Science and Business Media LLC

Subject

Immunology

Link

http://link.springer.com/content/pdf/10.1186/s12865-018-0262-z.pdf

Reference55 articles.

1. Zamora AE, Grossenbacher SK, Aguilar EG, Murphy WJ. Models to Study NK Cell Biology and Possible Clinical Application. Curr Protoc Immunol. 2015;110(14 37):11–4.

2. Kumar S. Natural killer cell cytotoxicity and its regulation by inhibitory receptors. Immunology. 2018;154(3):383–93.

3. Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med. 2009;266(2):154–81.

4. Davis ZB, Felices M, Verneris MR, Miller JS. Natural killer cell adoptive transfer therapy: exploiting the first line of defense against Cancer. Cancer J. 2015;21(6):486–91.

5. Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR, Burger SR, Panoskaltsis-Mortari A, Keever-Taylor CA, Zhang MJ, et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Bone Marrow Transplant. 2003;32(2):177–86.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies;Biological Chemistry;2024-05-21

2. Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands;International Journal of Molecular Sciences;2024-04-26

3. Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review;Frontiers in Immunology;2024-04-17

4. Limited Clinical Efficacy with Potential Adverse Events in a Pilot Study of Autologous Adoptive Cell Therapy in Canine Oral Malignant Melanoma;Veterinary Sciences;2024-03-28

5. Breakthrough of solid tumor treatment: CAR-NK immunotherapy;Cell Death Discovery;2024-01-20